The role of extracellular serotonin and MDMA in the sensitizing effects of MDMA

MDMA (3,4-methylenedioxymethamphetamine) is an amphetamine analogue with strong monoamine-releasing properties, particularly potent for serotonin (5-HT). Despite the prominent serotonergic actions of MDMA — a profile that typically does not predict high abuse liability — humans misuse MDMA and laboratory animals will self-administer it. Previous work has shown that repeated MDMA exposure can produce behavioural sensitization (enhanced locomotor and reinforcing effects) and that chronic or high-dose MDMA exposure often produces persistent deficits in markers of 5-HT neurotransmission (for example, reduced tissue 5-HT, lower serotonin transporter density, and diminished MDMA-induced 5-HT release). Given that increased 5-HT transmission generally suppresses stimulant self-administration, the authors hypothesised that reductions in 5-HT signalling after repeated MDMA might disinhibit MDMA reinforcement and contribute to sensitization. Van De Wetering and colleagues set out to test whether a behaviourally sensitizing regimen of repeated MDMA altered the medial striatal extracellular concentrations of 5-HT produced by acute MDMA, and whether changes in systemic MDMA pharmacokinetics could account for sensitisation. To address this, they applied in vivo microdialysis combined with liquid chromatography–mass spectrometry (LC–MS) to quantify both extracellular 5-HT and MDMA in the medial striatum while measuring locomotor activity after ascending acute MDMA doses in rats previously pre-treated with MDMA or saline.

Male Sprague-Dawley rats (~12 weeks old) were used (initial n = 24). Animals were pair-housed until ~10 weeks of age, then singly housed. Rats were stereotaxically implanted with guide cannulae targeting the medial striatum (coordinates relative to bregma given in the paper). Probe placements were verified histologically and animals with placements outside the target region were excluded. The pre-treatment regimen comprised once-daily intraperitoneal injections of either saline (n = 12) or MDMA 10 mg/kg (n = 12) for five consecutive days, with locomotor activity recorded during each pre-treatment session (30 min baseline, then 60 min post-injection). After two drug-free days, microdialysis probes were implanted and, three hours later, rats received ascending acute MDMA doses (0.0, 5.0, 10.0 mg/kg i.p.) given at 2-hour intervals. Dialysate samples were collected every 30 minutes for 2 hours before and after each acute dose, and locomotor activity was recorded concurrently and summed to 30-min bins to match sampling. Microdialysis probes had a membrane area of 0.5 mm × 3 mm and a flow rate of 0.5 µL/min; in vitro relative recovery was ~45% at that flow. Samples (15 µL) were derivatized using benzoyl chloride (BzCl) with an internal standard (D2-5-HT) before storage at -80 °C. Analysis used LC–MS (Q-TOF LCMS referenced in the paper). External calibration standards were prepared for 5-HT (0–10 nM) and MDMA (0–10 µM); 5-HT concentrations were quantified using weighted linear calibration curves relative to the internal standard, while MDMA concentrations used a non-weighted quadratic curve due to detector saturation at high concentrations. Statistical analysis used mixed-measures ANOVAs: 2 (pre-treatment: saline vs MDMA 10 mg/kg) × 16 (time: 30–480 min) for timecourses, and 2 (pre-treatment) × 4 (acute MDMA dose: baseline, 0.0, 5.0, 10.0 mg/kg) for area-under-the-curve (AUC) analyses. Follow-up tests included Dunnett’s comparisons to baseline and Tukey pairwise tests; Greenhouse–Geisser corrections were applied when sphericity was violated. Significance was set at p < .05.

Data from 21 of 24 rats were analysed (two rats did not complete pre-treatment, one had incorrect probe placement). Locomotor activity showed a significant interaction between pre-treatment and time, F(2.76, 52.50) = 4.19, p = .012, partial η2 = .181, indicating that acute MDMA produced time-dependent increases in locomotion that were enhanced by prior MDMA exposure. Simple main effects of time were significant within both groups. Compared with the 120 min pre-injection baseline, saline-pretreated rats showed a significant locomotor increase at 480 min, whereas MDMA-pretreated rats showed significant increases at 300 min and from 390–480 min (p < .05). Direct group comparisons revealed greater MDMA-induced locomotion in the MDMA pre-treatment group at 300, 330, 390, 420, and 450 min (p < .05). AUC analyses (pre-treatment × acute MDMA dose) also showed a significant interaction, F(1.65, 31.34) = 9.74, p = .001, partial η2 = .339. Both groups exhibited dose effects: saline-pretreated rats had significant locomotor increases only after 10 mg/kg, whereas MDMA-pretreated rats showed significant increases after both 5 and 10 mg/kg (p < .05). Overall, prior MDMA exposure sensitised the locomotor response to acute MDMA. Extracellular MDMA concentrations in medial striatum increased after acute MDMA in a dose-dependent manner but were not altered by MDMA pre-treatment. Timecourse analysis showed a main effect of time, F(15, 285) = 97.66, p < .001, partial η2 = .837, with concentrations increasing from 270–480 min relative to baseline (p < .05). There was no significant pre-treatment × time interaction or main effect of pre-treatment (p > .05). AUC analyses confirmed a significant main effect of acute MDMA dose, F(1.31, 24.91) = 137.32, p < .001, partial η2 = .878, with higher MDMA concentrations after 5 and 10 mg/kg (p < .05) but no effect of prior treatment. Extracellular 5-HT (serotonin) in the medial striatum increased dose-dependently following acute MDMA; the main effect of dose in the AUC analysis was F(1.94, 36.84) = 158.31, p < .001, partial η2 = .893, with significant increases after both 5 and 10 mg/kg (p < .05). However, MDMA pre-treatment did not significantly affect 5-HT concentrations (no main effect of pre-treatment and no significant interaction, p > .05). The authors additionally report that the total increase in MDMA concentrations after 10 mg/kg was approximately 2.64-fold greater than after 5 mg/kg, whereas the 5-HT increase after 10 mg/kg was only about 1.35-fold greater than after 5 mg/kg, suggesting a relative saturation of 5-HT release at higher MDMA concentrations.

The study developed and applied a microdialysis plus Q‑TOF LC–MS procedure to quantify extracellular 5-HT and MDMA in the medial striatum during acute MDMA challenges after a sensitising pre-treatment regimen. Behavioural results replicated earlier findings: acute MDMA produced dose-dependent locomotor stimulation that was enhanced by prior intermittent MDMA exposure. Neurochemically, acute MDMA produced dose-dependent increases in both extracellular MDMA and 5-HT in the medial striatum, but prior MDMA exposure did not alter the MDMA concentrations measured in dialysates nor the MDMA-induced 5-HT overflow. These results argue against changes in medial-striatal MDMA pharmacokinetics or MDMA-evoked 5-HT synaptic overflow as primary mechanisms underlying the sensitised locomotor and reinforcing effects observed after this pre-treatment regimen. Van De Wetering and colleagues note that other 5-HTergic mechanisms (for example, alterations in receptor densities or changes in 5-HT release in other brain regions) remain possible contributors, but emphasise that the current data do not support a reduced MDMA-evoked 5-HT release in the medial striatum as the driver of sensitisation for the regimen tested. The investigators highlight dopamine (DA) as a likely alternative mechanism. They point to prior studies showing increased DAergic neurotransmission, elevated DA tissue levels, enhanced MDMA-induced DA release, increased striatal neuron firing and dendritic spine density, and pharmacological data where D1 or D2 antagonists prevented expression or development of MDMA sensitization. Another notable observation was evidence for saturation of 5-HTergic effects: although extracellular MDMA rose substantially from 5 to 10 mg/kg (reported as ~2.64-fold), 5-HT increases showed only a modest further rise (~1.35-fold), consistent with saturation of transporter-mediated 5-HT release at higher MDMA concentrations. The authors suggest that saturation of 5-HT mechanisms could disinhibit DAergic effects at higher MDMA brain concentrations, making DAergic mechanisms relatively more important at higher doses or during self-administration. Finally, the authors acknowledge that the absence of detectable 5-HT deficits in this study likely reflects the exposure regimen used; larger cumulative exposure or different patterns of dosing are required to produce the persistent 5-HTergic deficits reported elsewhere. They conclude that future work should examine other brain regions, receptor-level changes, and DAergic processes to clarify the mechanisms of MDMA sensitization.